Cover Image
市場調查報告書

白內障:開發中產品分析

Cataract - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 200936
出版日期 內容資訊 英文 43 Pages
訂單完成後即時交付
價格
Back to Top
白內障:開發中產品分析 Cataract - Pipeline Review, H1 2017
出版日期: 2017年05月16日 內容資訊: 英文 43 Pages
簡介

白內障是一般正常時為透明的水晶體模糊,而漸漸失去視力這樣的疾病。主要症狀為視野蒙上陰影,模糊朦朧,及夜間視物困難,失去色覺或變黃,單眼複視,眼鏡度數頻繁改變等。主要易罹病素質有年齡和糖尿病、飲酒過度、高血壓、肥胖、抽煙等。

本報告提供全球各國治療白內障所用之開發中產品開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

白內障 - 概要

白內障 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

白內障 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

白內障的開發治療藥的企業

  • Acucela Inc
  • EyeGate Pharmaceuticals Inc
  • Genisphere LLC
  • Johnson & Johnson
  • Omeros Corp
  • Plex Pharmaceuticals Inc

藥物簡介

白內障 - 暫停中的計劃

白內障 - 開發中止的產品

白內障 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9287IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cataract - Pipeline Review, H1 2017, provides an overview of the Cataract (Ophthalmology) pipeline landscape.

Cataract is a clouding of the normally clear lens of eye that affects vision. Symptoms include clouded, blurred or dim vision, increasing difficulty with vision at night, fading or yellowing of colors, double vision in a single eye and frequent prescription changes in eye wear. Risk factors include age, diabetes, drinking excessive amounts of alcohol, high blood pressure, obesity and smoking.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cataract - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Cataract (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cataract (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Cataract and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 6 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Cataract (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cataract (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Cataract (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cataract (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cataract (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cataract (Ophthalmology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cataract (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cataract (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cataract - Overview
    • Cataract - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Cataract - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cataract - Companies Involved in Therapeutics Development
    • Acucela Inc
    • EyeGate Pharmaceuticals Inc
    • Genisphere LLC
    • Johnson & Johnson
    • Omeros Corp
    • Plex Pharmaceuticals Inc
  • Cataract - Drug Profiles
    • CAT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CAT-811 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dexamethasone acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GL-249 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lanosterol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Non-Surgical Cataracts and Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize GPR161 for Central Nervous System Disorders, Oncology and Ophthalmology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules for Ophthalmology and CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Target Beta-L Crystallin for Cataract and Presbyopia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VP-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cataract - Dormant Projects
  • Cataract - Discontinued Products
  • Cataract - Product Development Milestones
    • Featured News & Press Releases
      • Sep 07, 2016: Plex Pharmaceuticals awarded $299,173 NIH Phase I SBIR grant funding to find non-surgical treatments for Cataracts
      • May 13, 2012: Calpain Therapeutics Wins Commercialisation Australia Grant To Progress Anti-Cataract Programme
      • Sep 04, 2011: New Drug Eyes Way To Beat Cataracts
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Cataract, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Cataract - Pipeline by Acucela Inc, H1 2017
  • Cataract - Pipeline by EyeGate Pharmaceuticals Inc, H1 2017
  • Cataract - Pipeline by Genisphere LLC, H1 2017
  • Cataract - Pipeline by Johnson & Johnson, H1 2017
  • Cataract - Pipeline by Omeros Corp, H1 2017
  • Cataract - Pipeline by Plex Pharmaceuticals Inc, H1 2017
  • Cataract - Dormant Projects, H1 2017
  • Cataract - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Cataract, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top